Paris, January 4, 2016 – Baker & McKenzie advised Accenture on the acquisition of Boomerang Pharmaceutical Communications.  The e-marketing agency was represented by DLA Piper.

With this acquisition, Accenture has reinforced its expertise in e-consulting and e-marketing with its clients operating in the pharmaceutical, biotechnologies and medical instruments sectors, specifically in Europe.  As a result, Accenture now has new skills for the development and promotion of digital campaigns, web content and marketing operations.

Accenture is a global leader in consulting services and technologies and assists large companies in their transformation, from strategy to implementation.  With more than 358,000 employees, Accenture operates in more than 120 countries, in various sectors, to increase the performance of its clients and transform their organizations, distribution modes and client relations.

Boomerang Pharmaceutical Communications is a global e-marketing agency specialized in the pharmaceutical, biotechnologies and medical instruments sectors based in Basel.  The agency has dealt with digital strategy, e-marketing and development of websites for more than 17 years and employs more than 80 people.

Accenture was represented by Baker & McKenzie Paris with Alain Sauty de Chalon (Partner), assisted by Savéria Laforce (Senior Associate) and Giuliano Lastrucci (Associate) for the corporate aspects and with Guillaume Le Camus (Partner) and Edouard de Rancher (Senior Associate) for the tax aspects. The Zurich and Chicago offices of Baker & McKenzie were also involved.

Boomerang Pharmaceutical Communications was represented by DLA Piper with Laurence Masseran (Partner) and Nicolas Lovas (Associate) for the corporate aspects and by Hervé Israel (Partner) and Charles-Antoine del Valle (Associate) for the tax aspects.

KPMG Transaction Services, with Antoine Bernabeu (Partner), dealt with the assignment aspects.